These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 22571611)

  • 21. Small molecules targeting microRNAs: new opportunities and challenges in precision cancer therapy.
    Jurj A; Fontana B; Varani G; Calin GA
    Trends Cancer; 2024 Sep; 10(9):809-824. PubMed ID: 39107162
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacological inhibitors of autophagy as novel cancer therapeutic agents.
    Wang C; Hu Q; Shen HM
    Pharmacol Res; 2016 Mar; 105():164-75. PubMed ID: 26826398
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of anticancer agents targeting the Hedgehog signaling.
    Zhang X; Tian Y; Yang Y; Hao J
    Cell Mol Life Sci; 2017 Aug; 74(15):2773-2782. PubMed ID: 28314894
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epigenetic opportunities and challenges in cancer.
    Best JD; Carey N
    Drug Discov Today; 2010 Jan; 15(1-2):65-70. PubMed ID: 19897050
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting DNA methylation with small molecules: what's next?
    Erdmann A; Halby L; Fahy J; Arimondo PB
    J Med Chem; 2015 Mar; 58(6):2569-83. PubMed ID: 25406944
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting components of epigenome by small molecules.
    You JS; Han JH
    Arch Pharm Res; 2014 Nov; 37(11):1367-74. PubMed ID: 25070764
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Progress in the development of small molecule therapeutics targeting Th17 cell function for the treatment of immune-inflammatory diseases.
    Shuttleworth S; Townsend P; Silva F; Cecil A; Hill T; Tomassi C; Rogers H; Harrison R
    Prog Med Chem; 2011; 50():109-33. PubMed ID: 21315929
    [No Abstract]   [Full Text] [Related]  

  • 28. ELR+ CXC chemokines and their receptors (CXC chemokine receptor 1 and CXC chemokine receptor 2) as new therapeutic targets.
    Bizzarri C; Beccari AR; Bertini R; Cavicchia MR; Giorgini S; Allegretti M
    Pharmacol Ther; 2006 Oct; 112(1):139-49. PubMed ID: 16720046
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chemical screening in zebrafish for novel biological and therapeutic discovery.
    Tan JL; Zon LI
    Methods Cell Biol; 2011; 105():493-516. PubMed ID: 21951544
    [TBL] [Abstract][Full Text] [Related]  

  • 30. K(+) channels as therapeutic targets in oncology.
    Stühmer W; Pardo LA
    Future Med Chem; 2010 May; 2(5):745-55. PubMed ID: 21426201
    [TBL] [Abstract][Full Text] [Related]  

  • 31. IAP antagonists: promising candidates for cancer therapy.
    Mannhold R; Fulda S; Carosati E
    Drug Discov Today; 2010 Mar; 15(5-6):210-9. PubMed ID: 20096368
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting the ubiquitin-proteasome pathway with inorganic compounds to fight cancer: a challenge for the future.
    Dalla Via L; Nardon C; Fregona D
    Future Med Chem; 2012 Mar; 4(4):525-43. PubMed ID: 22416778
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chemokine receptor expression on dendritic cells is normal in HIV-infected patients with a stable response to art, but chemokine levels remain elevated.
    Lee S; Fernandez S; French M; Price P
    J Med Virol; 2011 Jul; 83(7):1128-33. PubMed ID: 21567418
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction of CXC and CC chemokines by all-trans retinoic acid in acute promyelocytic leukemia cells.
    Shibakura M; Niiya K; Niiya M; Asaumi N; Yoshida C; Nakata Y; Tanimoto M
    Leuk Res; 2005 Jul; 29(7):755-9. PubMed ID: 15927671
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advances in small-molecule drug discovery for triple-negative breast cancer.
    Fosu-Mensah N; Peris MS; Weeks HP; Cai J; Westwell AD
    Future Med Chem; 2015; 7(15):2019-39. PubMed ID: 26495746
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Return of D
    Lindsley CW; Hopkins CR
    J Med Chem; 2017 Sep; 60(17):7233-7243. PubMed ID: 28489950
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug development of MET inhibitors: targeting oncogene addiction and expedience.
    Comoglio PM; Giordano S; Trusolino L
    Nat Rev Drug Discov; 2008 Jun; 7(6):504-16. PubMed ID: 18511928
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of Small Molecule Modulators of MicroRNA by Library Screening.
    Xiao Z; Chen Y
    Methods Mol Biol; 2017; 1517():169-178. PubMed ID: 27924482
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibiting aberrant Stat3 function with molecular therapeutics: a progress report.
    Haftchenary S; Avadisian M; Gunning PT
    Anticancer Drugs; 2011 Feb; 22(2):115-27. PubMed ID: 21063201
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interferon-inducible protein 10 induction and inhibition of angiogenesis in vivo by the antitumor agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
    Cao Z; Baguley BC; Ching LM
    Cancer Res; 2001 Feb; 61(4):1517-21. PubMed ID: 11245459
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.